Lytix Biopharma ASA · OSL:LYTIX

Lytix Biopharma ASA — Q3 2023 Earnings Presentation

28 slides from Lytix Biopharma ASA's earnings presentation, Nov 9, 2023

  1. Slide 1: Lytix Biopharma AS Third quarter 2023 presentation

    Lytix Biopharma AS Encouraging efficacy signal emerging in ongoing Phase II trial Third quarter 2023 presentation November 9, 2023

  2. Slide 2: Disclaimer

    Disclaimer This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’relevant persons’). Any person

  3. Slide 3: Presenting team

    Presenting team Øystein Rekdal – CEO and co-founder • Dr. Rekdal’s post-doctoral research forms the basis of Lytix Biopharma’s technology platform. • Over the last years Rekdal has been instrumental in the development of intra-tumoral therapy of LTX-315 from preclinical to clinical ‘proof of concept

  4. Slide 4: Scientifically and commercially validated technology

    Scientifically and commercially validated technology Unique oncology technology platform Innovative pipeline that overcomes major with broad pipeline opportunities challenges in cancer therapy • Lead candidate; one completed and • Tumor heterogeneity promising preliminary results in two • Cold tumor

  5. Slide 5: Highlights for the third quarter

    Highlights for the third quarter - and post-period events ATLAS -IT-05 – Encouraging preliminary data presented at ESMO 2023 ‒ Disease control rate of 43% and one patient achieving a partial response to date ‒ There is evidence of tumor shrinkage in both injected and non-injected lesions Verrica Pha

  6. Slide 6: Clinical/Operational update

    Clinical/Operational update

  7. Slide 7: ATLAS-IT-05

    ATLAS-IT-05 - Phase II study with LTX-315 and pembrolizumab in late-stage melanoma patients refractory to immune checkpoint inhibitors A study in advanced melanoma patients who have US sites failed prior anti-PD-1/PD-L1 immune checkpoint therapy Aim of the study is to show whether LTX-315 has additi

  8. Slide 8: Summary based on first data snapshot

    Summary based on first data snapshot Early safety data (20 patients) and clinical efficacy data (14 patients) ‒ Median duration of follow-up was 15 weeks The combination regimen demonstrates preliminary signs of tumor shrinkage and prolonged stabilization in heavily pre-treated patients with PD-1/PD

  9. Slide 9: Response in injected lesions

    Response in injected lesions  9 out of 21 (43%) evaluable injected lesions showed 100% complete regression by CT scan after start of treatment  Any partial responses were not captured in this assessment by CT  Updated and more mature data on responses in injected lesions will be presented in the

  10. Slide 10: Response in injected lesions

    Response in injected lesions  Patient with multiple large tumor lesions on right forearm that were injected with LTX-315*  Clear signs of necrosis and regression of injected tumor lesions on Day 43 *Patient was technically classified as PD due to emergence of a small lesion in the finger and the p

  11. Slide 11: Case #1 - Melanoma patient with clinically relevant local and systemic response

    Case #1 - Melanoma patient with clinically relevant local and systemic response 75-year-old male, Stage IVm1a, melanoma (BRAF positive) Multiple metastases in lymph nodes and gluteal muscle at baseline Prior treatment with nivolumab and BRAF/Mek inhibitor 11

  12. Slide 12: Case #2 – Melanoma patient with systemic response but PD due to new lesion

    Case #2 – Melanoma patient with clinically systemic response but PD due to new lesion 77-year-old female patient with stage Two non-injected lesions (TL01 IVm1a melanoma and TL02) reduced in size (- Prior treatment: 36%) nivolumab Treated 1 lesion on 6 prescribed dosing days One new lesion (TL03 - l

  13. Slide 13: Planned neoadjuvant study with LTX-315 in earlier stage melanoma patients

    Planned neoadjuvant study with LTX-315 in earlier stage melanoma patients Neoadjuvant LTX-315 added to the currently recommended neoadjuvant treatment (immune checkpoint inhibitor, pembrolizumab) for resectable stage III/IV melanoma Principal investigator, dr. Henrik Jespersen, Head of melanoma onco

  14. Slide 14: Verrica Pharmaceuticals

    Verrica Pharmaceuticals - Phase II study in good progress Verrica reported promising interim Phase II data with LTX-315 (VP-315) at the 2023 AAD Innovation Meeting on August 11th In the presentation, Dr. Neal Bhatia MD, Director of Clinical Dermatology Therapeutics Clinical Research in San Diego, st

  15. Slide 15: Positive early results from ongoing Phase II study in basal cell carcinoma

    Positive early results from ongoing Phase II study in basal cell carcinoma ‒ Of the six patients treated with LTX-315 at the highest dose, complete clearance was observed in four injected lesions, 95% and 30% clearance in two other injected lesions Phase II study expected to be completed mid 2024 15

  16. Slide 16: A success in basal cell carcinoma represents a significant value increase for Lytix

    A success in basal cell carcinoma represents a significant value increase for Lytix Current treatment(s) for BCC are invasive, painful, disfiguring, and may require destruction of healthy tissue • LTX-315 represent a non-surgical alternative for patients suffering from skin cancer The BCC market siz

  17. Slide 17: Pipeline

    Pipeline Product Description Indication Discovery Preclinical Phase I Phase II Phase III candidate ATLAS-IT-05 Melanoma patients Pembrolizumab progressed on (Keytruda®) checkpoint inhibitors Phase II by Verrica Pharmaceuticals Basal cell carcinoma (monotherapy) LTX-315 Neoadjuvant ATLAS-IT-06 resect

  18. Slide 18: Key figures

    Key figures

  19. Slide 19: Key figures – profit and loss

    Key figures – profit and loss Unaudited Unaudited Amounts in NOK thousands Q3 2023 Q3 2022 FY 2022 Total operating income 4,292 2,972 17,273 Total operating expenses (22,936) (20,915) (82,968) Loss from operations (18,643) (17,944) (65,695) Loss for the period (18,248) (11,148) (56,006) Total operat

  20. Slide 20: Key figures

    Key figures 40 000 30 000 Total operating expense Direct R&D expenses 25 000 30 000 20 000 20 000 15 000 10 000 10 000 5 000 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2023 2022 2023 2022 40 000 Operating expenses 22/23 200 000 Cash and short term financial investments 30 000 150 000 20 000 100 000 10 000 0 50 000

  21. Slide 21: Key figures – balance sheet

    Key figures – balance sheet Unaudited Unaudited Amounts in NOK thousands 30.09.2023 30.09.2022 31.12.2022 Assets Property, plant and equipment 127 137 124 Trade and other receivables 1,252 5,656 6,735 Short-term financial investments 32,609 49,909 50,606 Cash and cash equivalents 46,158 121,671 94,5

  22. Slide 22: Outlook

    Outlook

  23. Slide 23: Key objectives

    Key objectives Clinical development ‒ Continue to monitor the 20 patients enrolled in ATLAS-IT-05 study (Top line data will be shared Q1 2024) ‒ An amendment for the initiation of an expansion cohort with up to 20 additional patients in process to be submitted ‒ Continue to support Verrica Pharmaceu

  24. Slide 24: Q&A

    Q&A IR enquiries: gjest.breistein@lytixbiopharma.com

  25. Slide 25: Interim Financial Statements

    Interim Financial Statements

  26. Slide 26: Condensed Interim statement of profit and loss

    Condensed Interim statement of profit and loss Unaudited Unaudited Unaudited Unaudited Amounts in NOK thousands Q3 2023 Q3 2022 YTD 2023 YTD 2022 FY 2022 Revenue 3,917 1,409 3,991 1,409 1,409 Other operating income 375 1,563 1,125 14,249 15,864 Total operating income 4,292 2,972 5,116 15,658 17,273

  27. Slide 27: Condensed Interim statement of financial position

    Condensed Interim statement of financial position Unaudited Unaudited Amounts in NOK thousands 30.09.2023 30.09.2022 31.12.2022 Assets Non-current assets Property, plant and equipment 127 137 124 Total non-current assets 127 137 124 Current assets Trade and other receivables 1,252 5,656 6,735 Short-

  28. Slide 28: Condensed Interim statement of cash flows

    Condensed Interim statement of cash flows Unaudited Unaudited Unaudited Unaudited Amounts in NOK thousands Q3 2023 Q3 2022 YTD 2023 YTD 2022 FY 2022 Cash flows from operating activities Loss for the period (18,248) (11,148) (69,357) (26,812) 56,006) Adjustments for: Depreciation of property, plant a

Lytix Biopharma AS — Q3 2023 Earnings Presentation on 6ix